Probiotics Role in HPV Cervico-vaginal Infection Clearance

Status Completed

Clinical Trial Summary

Vaginal infections demonstrated to be implicated in the persistence of HPV, activating a vicious circle of vaginal microbial perturbations. HPV infection can destroy the biofilm barrier formed by the local vaginal immune microenvironment, leading to a condition called dysbiosis. Contemporarily, the resulting local microecological imbalance in the vagina can subsequently upregulate the expression of the HPV protein, increasing HPV-related cytological alterations.

Clinical Trial Description

A total of 483 women affected by different vaginal infections and concomitant HPV-positivity were enrolled between 2018 and 2020 at Department of Gynecological, Obstetrical and Urological Sciences, University "Sapienza" of Rome (Rome, Italy) and 2nd Division of Obstetrics and Gynecology, Azienda Ospedaliera Universitaria Pisana, University of Pisa (Pisa, Italy). Women with positive swabs for infections were randomized in two groups, standard specific treatment (n=231) versus the standard treatment plus long-lasting (9 months) vaginal and oral probiotics implementation (n=252). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05109533
Study type	Interventional
Source	Azienda Ospedaliero, Universitaria Pisana
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2018
Completion date	March 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04098744` - Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)	Phase 2
Completed	`NCT04083196` - A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years	Phase 1
Completed	`NCT04191967` - Thermocoagulation for Treatment of Precancerous Cervical Lesions	N/A
Withdrawn	`NCT04430907` - HPV Vaccine in Postpartum Women
Recruiting	`NCT02593968` - Yallaferon in Chinese Population	Phase 2
Completed	`NCT04711265` - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Completed	`NCT02263378` - A New Supplement for the Immune Response to HPV Infection	N/A
Completed	`NCT05234112` - Prevention and Screening Towards Elimination of Cervical Cancer	N/A
Completed	`NCT04590521` - HPV Vaccine Immunity in High-risk Women	Phase 4
Recruiting	`NCT05829629` - Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women	Phase 1
Recruiting	`NCT06052033` - Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection	N/A
Recruiting	`NCT05051852` - HPV Viral Load in Predicting the Prognosis of LSIL
Completed	`NCT04155294` - Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
Active, not recruiting	`NCT06452004` - Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)	N/A
Completed	`NCT06177236` - Clinic or Self-Sampling for Cervical Cancer Screening	N/A
Active, not recruiting	`NCT04794660` - The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa"	Phase 3
Recruiting	`NCT05509413` - DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections	N/A
Recruiting	`NCT06137950` - Interferon Alpha Therapy for Cervical CINI and HPV Infection	Phase 1
Recruiting	`NCT04171505` - Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
Active, not recruiting	`NCT05524025` - The SPOT-HPV Study